How to appeal a Humana c. difficile infection denial

The framework that applies to your appeal

Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).

Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.

What Humana's policy requires for c. difficile infection

Cited policy: Humana Coverage for Vancomycin Enema in Fulminant / Severe-Complicated CDI

Severe-complicated or fulminant CDI per IDSA/SHEA 2021: hypotension, shock, ileus, OR toxic megacolon. Vancomycin 500 mg in 100 mL saline rectally q6h as adjunct to high-dose oral vancomycin (500 mg QID) + IV metronidazole 500 mg q8h. ICU-level / hospitalized care. Surgical consult documented.

How Humana denies c. difficile infection — and how to counter it

Where Humana pushes back: 1) Oral vancomycin sufficient; 2) Compounding not covered; 3) Off-label rectal route.

Counter-arguments that hold up: IDSA/SHEA 2021 Focused Update + ACG 2021 (Kelly AJG 2021;116:1124) explicitly recommend vancomycin retention enemas in fulminant CDI with ileus when oral delivery cannot reach the colon. Standard combination: oral vancomycin 500 mg QID + IV metronidazole 500 mg q8h + vancomycin enemas 500 mg q6h + emergent surgical consult. Documented megacolon (colon diameter >6 cm on CT), ileus, or hypotension qualifies as fulminant. Without rectal delivery in ileus, oral vancomycin does not reach affected colonic mucosa — life-threatening untreated. Cite specific section of IDSA/SHEA 2021 fulminant CDI recommendation.

What Humana typically denies for c. difficile infection

Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For c. difficile infection, expect:

• MA plan step therapy on Part B drugs
• Skilled nursing facility days
• Prior auth on specialty drugs
• OON emergency reduction

Treatments most often denied in this category

These are the c. difficile infection treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Fidaxomicin (Dificid)
• Fidaxomicin extended-pulsed
• Vancomycin PO
• Vancomycin enema
• Bezlotoxumab (Zinplava)
• Rebyota

How to submit the appeal to Humana

1. Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
3. File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.